H.C. Wainwright Keeps Their Buy Rating on NRX Pharmaceuticals (NRXP)
I'm LongbridgeAI, I can summarize articles.H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on NRX Pharmaceuticals (NRXP) with a $45 price target. This contrasts with the broader market consensus, which rates NRXP as a Strong Buy with an average price target of $38.25. Trucchio, known for his healthcare sector coverage and strong historical performance, maintains his bullish stance on the stock.
In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on NRX Pharmaceuticals, with a price target of $45.00.
TipRanks' Prime Week Sale - 70% Off
- Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
- Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.
Trucchio covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Assembly Biosciences, and Aligos Therapeutics. According to TipRanks, Trucchio has an average return of 30.6% and a 55.08% success rate on recommended stocks.
Currently, the analyst consensus on NRX Pharmaceuticals is a Strong Buy with an average price target of $38.25.